Skip to main content

Advertisement

SpringerLink
Log in

XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

XPA-210 is a proliferation marker derived from Thymidine kinase-1. It is of clinical significance in kidney, breast, and bladder cancer. There are no data available for XPA-210 in prostate cancer (PC). Herein, we aim to determine the clinical usefulness of XPA-210 in PC.

Materials and methods

In a retrospective study, cancer and benign tissue samples of 103 patients (median age 65 years, median PSA 9.04 ng/ml, median Gleason score 6) who underwent prostatectomy were constructed to a tissue micro array and stained for XPA-210. Semi-quantitative results were correlated with pathological and clinical data by Wilcoxon–Kruskall–Wallis and linear regression analysis. Expression levels in PC were correlated between the time of biochemical recurrence and the time to development of metastasis by the Kaplan–Meier method. Multivariate analysis was done to correlate those with the resection status.

Results

Mean staining score was 0.51–0.14 for tumor and benign tissue (P < 0.0001). Tumor staining score was significantly associated with Gleason score <6/≥6 (P < 0.0001) and T2/T >2 (P = 0.0007). When dividing the tumor score by the mean value, higher expression of XPA-210 was associated with a shorter time to biochemical recurrence (P = 0.003) and time to development of metastasis (P = 0.0061). Tumor staining (P = 0.0371) was an independent prognostic factor for biochemical relapse regardless of resection status.

Conclusions

XPA-210 is a new tissue-based prognostic marker for prostate cancer histopathology. It reliably differentiates tumor and normal prostatic tissue predicting biochemical relapse and onset of metastatic disease. XPA-210 might be clinically useful for individual decision-making in PC-treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. O’Donnell H, Parker C (2008) What is low-risk prostate cancer and what is its natural history? World J Urol 26(5):415–422

    Article  PubMed  Google Scholar 

  2. Postma R et al (2005) Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 103(4):708–716

    Article  PubMed  Google Scholar 

  3. Zellweger T et al (2009) Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 124(9):2116–2123

    Article  PubMed  CAS  Google Scholar 

  4. Nagao K et al (2011) Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml. Jpn J Clin Oncol 41:555–564

    Article  PubMed  Google Scholar 

  5. Hannigan BM et al (1993) Thymidine kinases: the enzymes and their clinical usefulness. Cancer Biother 8(3):189–197

    Article  PubMed  CAS  Google Scholar 

  6. Petty EM et al (1996) FISH localization of the soluble thymidine kinase gene (TK1) to human 17q25, a region of chromosomal loss in sporadic breast tumors. Cytogenet Cell Genet 72(4):319–321

    Article  PubMed  CAS  Google Scholar 

  7. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263(17):8350–8358

    PubMed  CAS  Google Scholar 

  8. Broet P et al (2001) Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19(11):2778–2787

    PubMed  CAS  Google Scholar 

  9. Chen Y et al (2010) Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol 15(4):359–368

    Article  PubMed  CAS  Google Scholar 

  10. Zhang J et al (2006) Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15(2):455–461

    PubMed  CAS  Google Scholar 

  11. Gakis G et al (2010) XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J Urol

  12. Mao Y et al (2005) Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep 13(5):837–846

    PubMed  CAS  Google Scholar 

  13. Wang N et al (2001) Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 23(1):11–19

    PubMed  Google Scholar 

  14. He Q et al (2004) Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25(4):945–953

    PubMed  CAS  Google Scholar 

  15. Vogel UF (2008) Simple, inexpensive and precise paraffin tissue microarrays constructed with predrilled ordinary steel embedding moulds. Histopathology 52(2):255–256

    PubMed  CAS  Google Scholar 

  16. Vogel UF (2009) The production of cast recipient blocks for paraffin tissue microarrays using conventional steel embedding moulds. Histopathology 55(4):470–472

    Article  PubMed  Google Scholar 

  17. Boccon-Gibod L et al (2004) Management of prostate-specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 58(4):382–390

    Article  PubMed  CAS  Google Scholar 

  18. Heidenreich A et al (2010) Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the association of urological oncology of the german cancer society. Urol Int 85(1):1–10

    Article  PubMed  Google Scholar 

  19. Wu C et al (2003) Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277(1–2):157–169

    Article  PubMed  CAS  Google Scholar 

  20. Zou L et al (2002) The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 17(2):135–140

    PubMed  CAS  Google Scholar 

  21. Rove KO, Flaig TW (2010) A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park) 24(14): 1308–1313, 1318

    Google Scholar 

  22. Ekman P, Lewenhaupt A (1991) Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information. Acta Oncol 30(2):173–175

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Anne-Charlotte Aronsson from Arocell provided the peptide for performing the antibody specificity experiments.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Eberhard-Karls University Tübingen, Hoppe-Seyler Strasse 3, 72076, Tübingen, Germany

    Stefan Aufderklamm, Jörg Hennenlotter, Tilman Todenhoefer, Georgios Gakis, David Schilling, Ursula Kuehs, Johannes Dlugosch, Valentina Gerber, Arnulf Stenzl & Christian Schwentner

  2. Institute of Pathology, Eberhard-Karls University, Tübingen, Germany

    Ulrich Vogel

  3. Department of Urology, Diakonie-Klinikum Stuttgart, Stuttgart, Germany

    Judith Knapp

  4. Department of Urology, Medical School Hannover, Hannover, Germany

    Axel Merseburger

  5. Department of Internal Medicine, Eberhard-Karls University, Tübingen, Germany

    Anna Ordelheide

  6. Alere North America, Inc., San Diego, CA, USA

    Joachim Hevler

Authors
  1. Stefan Aufderklamm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Hennenlotter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tilman Todenhoefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georgios Gakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Schilling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulrich Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ursula Kuehs
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Johannes Dlugosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Judith Knapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Axel Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Valentina Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Anna Ordelheide
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Joachim Hevler
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Arnulf Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Christian Schwentner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Schwentner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aufderklamm, S., Hennenlotter, J., Todenhoefer, T. et al. XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence. World J Urol 30, 547–552 (2012). https://doi.org/10.1007/s00345-011-0768-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-011-0768-y

Keywords

Search

Navigation